JP2011507599A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507599A5
JP2011507599A5 JP2010539515A JP2010539515A JP2011507599A5 JP 2011507599 A5 JP2011507599 A5 JP 2011507599A5 JP 2010539515 A JP2010539515 A JP 2010539515A JP 2010539515 A JP2010539515 A JP 2010539515A JP 2011507599 A5 JP2011507599 A5 JP 2011507599A5
Authority
JP
Japan
Prior art keywords
medical device
connexin
compound
item
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010539515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507599A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/014023 external-priority patent/WO2009085272A2/en
Publication of JP2011507599A publication Critical patent/JP2011507599A/ja
Publication of JP2011507599A5 publication Critical patent/JP2011507599A5/ja
Pending legal-status Critical Current

Links

JP2010539515A 2007-12-21 2008-12-22 改良医療デバイス Pending JP2011507599A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US873807P 2007-12-21 2007-12-21
PCT/US2008/014023 WO2009085272A2 (en) 2007-12-21 2008-12-22 Improved medical devices

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014187605A Division JP2015006440A (ja) 2007-12-21 2014-09-16 改良医療デバイス

Publications (2)

Publication Number Publication Date
JP2011507599A JP2011507599A (ja) 2011-03-10
JP2011507599A5 true JP2011507599A5 (enExample) 2013-04-25

Family

ID=40466841

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010539515A Pending JP2011507599A (ja) 2007-12-21 2008-12-22 改良医療デバイス
JP2014187605A Withdrawn JP2015006440A (ja) 2007-12-21 2014-09-16 改良医療デバイス
JP2016213448A Withdrawn JP2017064431A (ja) 2007-12-21 2016-10-31 改良医療デバイス
JP2018146805A Pending JP2018198954A (ja) 2007-12-21 2018-08-03 改良医療デバイス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014187605A Withdrawn JP2015006440A (ja) 2007-12-21 2014-09-16 改良医療デバイス
JP2016213448A Withdrawn JP2017064431A (ja) 2007-12-21 2016-10-31 改良医療デバイス
JP2018146805A Pending JP2018198954A (ja) 2007-12-21 2018-08-03 改良医療デバイス

Country Status (6)

Country Link
US (4) US9035037B2 (enExample)
EP (1) EP2234656A2 (enExample)
JP (4) JP2011507599A (enExample)
AU (1) AU2008343843A1 (enExample)
CA (1) CA2710386A1 (enExample)
WO (1) WO2009085272A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
CN105498074B (zh) * 2015-12-25 2017-08-08 李雷 血管壁修复系统
US20180028468A1 (en) * 2016-04-29 2018-02-01 Ocunexus Therapeutics, Inc. Sustained release drug delivery devices
RU2636418C1 (ru) * 2017-03-16 2017-11-23 Дмитрий Викторович Давыдов Способ коррекции экзофтальма и имплантат для увеличения объема орбиты в области сформированного костного дефекта при коррекции экзофтальма
WO2018199777A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
EP3746393A4 (en) 2018-02-02 2021-11-03 Galen Therapeutics Llc DEVICE AND METHOD FOR PROTECTING NEURONS AND REDUCING INFLAMMATION AND SCARING
EP4232157A4 (en) 2020-10-22 2024-08-28 Xequel Bio, Inc. PEPTIDE FORMULATIONS AND ASSOCIATED OPHTHALMIC USES
US20250289864A1 (en) * 2022-05-13 2025-09-18 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias
US20240299440A1 (en) * 2023-03-07 2024-09-12 Amber Ophthalmics, Inc. Novel treatments for ocular disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US4916193A (en) 1987-12-17 1990-04-10 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5092877A (en) 1988-09-01 1992-03-03 Corvita Corporation Radially expandable endoprosthesis
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US4994071A (en) 1989-05-22 1991-02-19 Cordis Corporation Bifurcating stent apparatus and method
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5163952A (en) 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5857998A (en) 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6566339B1 (en) 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
ES2293137T3 (es) 1995-10-11 2008-03-16 Novartis Vaccines And Diagnostics, Inc. Combinacion de pdgf, kgf,igf e igfbp para curacion de heridas.
EP0930876B2 (en) 1996-07-22 2010-07-07 Renovo Limited Use of compounds that promote oestrogenic activity for acclerating the healing of skin wounds
GB9702943D0 (en) 1997-02-13 1997-04-02 Univ Manchester Wound healing
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6855505B2 (en) 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
AU766826B2 (en) 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
DE19902481A1 (de) * 1999-01-22 2000-07-27 Signus Medizintechnik Gmbh Wirbelsäulenersatzkörper
CA2361251C (en) 1999-01-27 2011-03-08 David L. Becker Formulations comprising antisense nucleotides to connexins
GB9903598D0 (en) 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
JP2005509621A (ja) 2001-10-17 2005-04-14 ユニバーシティ オブ ウェールズ カレッジ オブ メディスン ギャップ結合ならびにedhf
CN1939529A (zh) 2002-01-29 2007-04-04 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
JP5838017B2 (ja) * 2003-12-03 2015-12-24 コーダ セラピューティクス, インコーポレイテッド コネキシンに対して標的化されたアンチセンス化合物およびその使用方法
HUE038099T2 (hu) 2004-12-21 2018-09-28 Musc Found For Res Dev Kompozíciók és módszerek sebgyógyulás és szöveti regeneráció elõsegítésére
US7829527B2 (en) * 2005-02-02 2010-11-09 University Of Vermont And State Agricultural College Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
AU2008335718A1 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments

Similar Documents

Publication Publication Date Title
Parent et al. Design of calcium phosphate ceramics for drug delivery applications in bone diseases: A review of the parameters affecting the loading and release of the therapeutic substance
ES2848562T3 (es) Procedimiento indirecto para reparación de tejido articular
JP5114801B2 (ja) 生体吸収性支持フレームを有するグラフト
CN102231992B (zh) 用于治疗肌腱和韧带损伤的血小板衍生生长因子的组合物和方法
US9585988B2 (en) Anchorage devices comprising an active pharmaceutical ingredient
JP6889193B2 (ja) 再狭窄の予防または治療のための化合物および方法
US20050202061A1 (en) Optimized dosing for drug coated stents
EP1723976A3 (en) Intraluminal medical devices in combination with therapeutic agents
JP5153340B2 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
US20150273119A1 (en) Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating
EP3056229A3 (en) The local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
JP2018198954A (ja) 改良医療デバイス
MX2010007571A (es) Endoprotesis eluyente con receptaculo de rapamicina.
ES2987568T3 (es) Cuerda de terapia de inserción de hilo y aparato de aguja de terapia de inserción de hilo que comprende la misma
DE602005022378D1 (de) Lokale, vaskuläre Verabreichung von 2-methoxyestradiol in Kombination mit Rapamycin zur Vorbeugung von Restenose nach Gefässverletzungen
Chou et al. Combination of a biodegradable three-dimensional (3D)–printed cage for mechanical support and nanofibrous membranes for sustainable release of antimicrobial agents for treating the femoral metaphyseal comminuted fracture
ATE475438T1 (de) Lokale, vaskuläre verabreichung von etoposide in kombination mit rapamycin zur vorbeugung von restenose nach gefässverletzungen
JP2011507859A5 (enExample)
WO2011031301A2 (en) Intrapericardial delivery of periostin
US20070129790A1 (en) Treatment of aneurysms with an implantable polymeric, biodegradable device incorporating a MMP inhibitor
JP2024532867A5 (enExample)
Kusanagi et al. Hydrogel-mediated release of basic fibroblast growth factor from a stent-graft accelerates biological fixation with the aortic wall in a porcine model
JP2002512951A5 (enExample)
Ward et al. Strategies to overcome biological barriers to biosensing
McMaster Ex-vivo Evaluation of a Modified Teno Fix® Device Repair Pattern Versus a Three-Loop Pulley for Repair of Equine Flexor Tendons